Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 23NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm, Residual 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 131Carboplatin 106Paclitaxel 66Cisplatin 61Gemcitabine 57Pemetrexed 56Bevacizumab 50Docetaxel 47Fluorouracil 40Oxaliplatin 38Dexamethasone 34130-nm albumin-bound paclitaxel 34Leucovorin 33atezolizumab 32Cetuximab 32durvalumab 30Nivolumab 28Rituximab 26Cyclophosphamide 26Capecitabine 26Prednisone 25Fulvestrant 24enzalutamide 23Lenalidomide 22venetoclax 21Letrozole 20Irinotecan 20Doxorubicin 17ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × fludarabine phosphate × 30 days × Clear all
NCT05712278 2026-06-05

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Sanofi

Phase 1 Terminated
7 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07627698 2026-06-04

DUET-MEL

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT06500273 2026-06-02

ALPHA3

Allogene Therapeutics

Phase 2 Recruiting
250 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡